Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- NP_056293 NP056293 L3M-BTL1 L3MBTL-1 H3K4-me1 H4K20-me2
- Product Overview:
Key Features Cayman’s L3MBTL1 MBT Domains TR-FRET Assay Kit (Item No. 601030) was developed using L3MBTL1 MBT domains (human recombinant; GST-tagged) protein.Bulk sizes available upon request “The malignant brain tumor (MBT) domain is structurally related to chromatin binding domains, such as chromodomains, tudor domains, and PWWP-domains.{24018,22297} MBT domain-containing proteins have a variable number of MBT repeats. The MBT domains recognize methylated lysines on histone tails with varying degree of specificity for the various methyl marks.{24018} L3MBTL1, a human homolog of the Drosophila lethal(3)MBT protein, is a member of the polycomb group (PcG) of proteins that functions as a transcriptional repressor.{24020} L3MBTL1 contains three MBT repeat domains which collectively bind to either histone H3 or H4.{24018,24022} The second and third MBT domains were found to bind preferentially to mono- and dimethylated lysines of histone H3 at lysine 4 (H3K4me1) and histone H4 at lysine 20 (H4K20me2).{24022,18035} Recognition of methyl-lysine marks by MBT domains leads to chromatin compaction and a repressed transcriptional state.{24022,24021} Further, L3MBTL1 has a tumor suppressor function and is thought to play a role in maintaining genomic stability and DNA replication.{24019,24017} This protein product contains the MBT repeat region of L3MBTL1.”
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.